Importer of Controlled Substances Application: Meridian Medical Technologies, 7129-7130 [2019-03688]
Download as PDF
<![CDATA[
7129
Federal Register / Vol. 84, No. 41 / Friday, March 1, 2019 / Notices
with either or both of these definitions,
please explain why and provide
alternative definitions.
DEPARTMENT OF JUSTICE
Authority: This proceeding is being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.61 of the
Commission’s rules.
[Docket No. DEA–392]
By order of the Commission.
Issued: February 22, 2019.
Lisa Barton,
Secretary to the Commission.
ACTION:
Drug Enforcement Administration
Bulk Manufacturer of Controlled
Substances Application: Siegfried
USA, LLC
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before April 30, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
DATES:
[FR Doc. 2019–03452 Filed 2–28–19; 8:45 am]
BILLING CODE 7020–02–P
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
November 5, 2018, Siegfried USA, LLC,
33 Industrial Park Road, Pennsville,
New Jersey 08070–3244 applied to be
registered as a bulk manufacturer of the
following basic classes of controlled
substances:
Controlled substance
Drug code
Gamma Hydroxybutyric Acid ...........................................................................................................................................
Dihydromorphine .............................................................................................................................................................
Hydromorphinol ...............................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
Amobarbital ......................................................................................................................................................................
Pentobarbital ....................................................................................................................................................................
Secobarbital .....................................................................................................................................................................
Codeine ...........................................................................................................................................................................
Oxycodone .......................................................................................................................................................................
Hydromorphone ...............................................................................................................................................................
Hydrocodone ...................................................................................................................................................................
Methadone .......................................................................................................................................................................
Methadone intermediate ..................................................................................................................................................
Morphine ..........................................................................................................................................................................
Oripavine .........................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Opium tincture .................................................................................................................................................................
Oxymorphone ..................................................................................................................................................................
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
Dated: February 11, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–03689 Filed 2–28–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
jbell on DSK30RV082PROD with NOTICES
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Meridian Medical
Technologies
ACTION:
Notice of application.
VerDate Sep<11>2014
18:13 Feb 28, 2019
Jkt 247001
Registered bulk manufacturers of
the affected basic class, and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration on or before April
1, 2019. Such persons may also file a
written request for a hearing on the
application on or before April 1, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
DATES:
PO 00000
Frm 00114
Fmt 4703
Sfmt 4703
2010
9145
9301
1724
2125
2270
2315
9050
9143
9150
9193
9250
9254
9300
9330
9333
9630
9652
Schedule
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
E:\FR\FM\01MRN1.SGM
01MRN1
7130
Federal Register / Vol. 84, No. 41 / Friday, March 1, 2019 / Notices
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on
November 19, 2018, Meridian Medical
Technologies, 2555 Hermelin Drive,
Saint Louis, Missouri 63144 applied to
be registered as an importer of the
following basic class of controlled
substance:
Controlled
substance
Drug code
Morphine ...
Schedule
9300
II
The company manufactures a product
containing morphine in the United
States. The company exports this
product to customers around the world.
The company has been asked to ensure
that its product, which is sold to
European customers, meets the
standards established by the European
Pharmacopeia, administered by the
Directorate for the quality of Medicines
(EDQM). In order to ensure that is
product will meet European
specifications, the company seeks to
import morphine supplied by EDQM for
use as reference standards.
Dated: February 13, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–03688 Filed 2–28–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1110–0069]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Revision of a
Currently Approved Collection; Flash/
Cancellation/Transfer Notice (I–12)
Criminal Justice Information
Services Division, Federal Bureau of
Investigation, Department of Justice.
ACTION: 60-day notice.
AGENCY:
Department of Justice (DOJ),
Federal Bureau of Investigation,
Criminal Justice Information Services
Division will be submitting the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until April
30, 2019.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
jbell on DSK30RV082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:13 Feb 28, 2019
Jkt 247001
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Gerry Lynn Brovey, Supervisory
Information Liaison Specialist, FBI,
CJIS, Resources Management Section,
Administrative Unit, Module C–2, 1000
Custer Hollow Road, Clarksburg, West
Virginia, 26306 (telephone: 304–625–
5093) or email glbrovey@fbi.gov. Written
comments and/or suggestions can also
be sent to the Office of Management and
Budget, Office of Information and
Regulatory Affairs, Attention
Department of Justice Desk Officer,
Washington, DC 20503. Additionally,
comments may be submitted via email
to OIRA_submission@omb.eop.gov.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the Bureau of Justice
Statistics, including whether the
information will have practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
1. Type of Information Collection:
Revision of a currently approved
collection.
2. The Title of the Form/Collection:
Flash/Cancellation/Transfer Notice.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
Agency form number: I–12. Sponsoring
component: Department of Justice,
Federal Bureau of Investigation,
Criminal Justice Information Services
Division.
PO 00000
Frm 00115
Fmt 4703
Sfmt 4703
4. Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: City, county, state,
federal and tribal law enforcement
agencies. This collection is needed to
indicate on an individual’s criminal
history that the individual is being
supervised to ensure the supervisory
agency is notified of any additional
criminal history activity. Acceptable
data is stored as part of the Next
Generation Identification (NGI) system
of the FBI.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 1,171
respondents will complete each form
within approximately 8 minutes.
6. An estimate of the total public
burden (in hours) associated with the
collection: There are an estimated
25,905 total annual burden hours
associated with this collection.
If additional information is required
contact: Melody Braswell, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE, 3E.405A,
Washington, DC 20530.
Dated: February 21, 2019.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2019–03301 Filed 2–28–19; 8:45 am]
BILLING CODE 4410–02–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (OJJDP) Docket No. 1578]
Meeting of the Federal Advisory
Committee on Juvenile Justice
Office of Juvenile Justice and
Delinquency Prevention, Department of
Justice.
ACTION: Notice of meeting.
AGENCY:
SUMMARY: The Office of Juvenile Justice
and Delinquency Prevention has
scheduled a meeting of the Federal
Advisory Committee on Juvenile Justice
(FACJJ).
DATES: Friday March 22nd, 2019 at 9:00
a.m.–4:30 p.m. EST.
ADDRESSES: The meeting will take place
in the third floor video conference room
at the U.S. Department of Justice, Office
of Justice Programs, 810 7th St. NW,
Washington, DC 20531.
FOR FURTHER INFORMATION CONTACT: Visit
the website for the FACJJ at
www.facjj.ojp.gov or contact Jeff
E:\FR\FM\01MRN1.SGM
01MRN1
]]>Agencies
[Federal Register Volume 84, Number 41 (Friday, March 1, 2019)]
[Notices]
[Pages 7129-7130]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-03688]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Meridian Medical
Technologies
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before April 1, 2019. Such
persons may also file a written request for a hearing on the
application on or before April 1, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant
[[Page 7130]]
Administrator of the DEA Diversion Control Division (``Assistant
Administrator'') pursuant to section 7 of 28 CFR part 0, appendix to
subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on
November 19, 2018, Meridian Medical Technologies, 2555 Hermelin Drive,
Saint Louis, Missouri 63144 applied to be registered as an importer of
the following basic class of controlled substance:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Morphine................................ 9300 II
------------------------------------------------------------------------
The company manufactures a product containing morphine in the
United States. The company exports this product to customers around the
world. The company has been asked to ensure that its product, which is
sold to European customers, meets the standards established by the
European Pharmacopeia, administered by the Directorate for the quality
of Medicines (EDQM). In order to ensure that is product will meet
European specifications, the company seeks to import morphine supplied
by EDQM for use as reference standards.
Dated: February 13, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-03688 Filed 2-28-19; 8:45 am]
BILLING CODE 4410-09-P
